$-0.69 EPS Expected for Acer Therapeutics Inc. (ACER) on May, 11

May 3, 2018 - By Carey Conley

Acer Therapeutics Inc. (NASDAQ:ACER)’s quarterly earnings will be reported on May, 11., as reported by Faxor. Analysts forecast $-0.69 EPS, which is $0.55 up or 44.35 % from 2017’s $-1.24 EPS. Wall Street now sees 9.52 % negative EPS growth despite Acer Therapeutics Inc. last quarter’s EPS of $-0.63. The stock decreased 0.11% or $0.02 during the last trading session, reaching $18.88.Acer Therapeutics Inc. has volume of 5,634 shares. Since May 3, 2017 ACER has risen 126.38% and is uptrending. The stock outperformed the S&P 500 by 114.83%.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs.The company has $141.55 million market cap. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease .Currently it has negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

Acer Therapeutics Inc. (NASDAQ:ACER) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: